Pomerantz Law Firm Files Class Action Against Inovio Pharmaceuticals Over Alleged Securities Violations

Pomerantz Law Firm Files Class Action Against Inovio Pharmaceuticals

In a significant step for investors of Inovio Pharmaceuticals, Inc., the Pomerantz Law Firm has announced the filing of a class action lawsuit against the company and certain of its officers. This lawsuit, rooted in allegations of violations of federal securities laws, seeks to recover damages for individuals and entities that purchased or acquired Inovio securities between October 10, 2023 and December 26, 2025, a period referred to as the “Class Period.”

Background of the Class Action

Filed in the United States District Court for the Eastern District of Pennsylvania under the docket number 26-cv-00803, the lawsuit represents a class of investors hoping to hold the defendants accountable. The period in question encompasses a time when numerous favorable statements about Inovio’s business operations and product development were made, likely influencing investor decisions.

Investors who believe they are part of this class need to act quickly, as they have until April 7, 2026, to request the court to appoint them as Lead Plaintiff. Individuals seeking more information about the case can find a copy of the Complaint and further details on the Pomerantz Law Firm's website. A dedicated contact, Danielle Peyton, has been assigned to address inquiries regarding the lawsuit.

Details About Inovio Pharmaceuticals

Inovio Pharmaceuticals is a biotech company specializing in the discovery and development of DNA medicines aimed at combatting serious diseases, including those related to human papilloma virus (HPV). The core of their medical innovation is the combination of DNA plasmids, which function like software enabling cells to produce disease-fighting proteins, along with the proprietary medical device known as “CELLECTRA.” This device helps in delivering these DNA medicines into the body’s cells for enhanced efficacy.

One of Inovio’s lead product candidates is identified as INO-3107, projected for the treatment of recurrent respiratory papillomatosis (RRP), a rare but life-long condition linked to HPV infection. Over time, the company’s executives conveyed optimistic promises regarding the potential for FDA accelerated approval of INO-3107 and the completion timeline for its Biologics License Application (BLA), setting high expectations for investors.

However, as the class period unfolded, several discrepancies emerged that contradicted the optimistic narrative presented by the company's leadership. Key among them were concerns regarding the manufacturing quality of the CELLECTRA device and inadequate information regarding the eligibility for FDA accelerated approval of INO-3107.

Misleading Statements and Market Impact

Throughout the class period, the defendants allegedly disseminated materially false and misleading statements about Inovio’s capabilities and prospects. It was claimed that manufacturing processes were deficient and timelines for regulatory approvals were overstated. As a result, when the reality of these issues began to surface, it caused significant stock price declines.

For instance, in August 2024, Inovio announced a delay in the submission of the INO-3107 BLA to the FDA, adjusting their timeline by nearly a full year. This revelation led to a noticeable drop in share value, falling by approximately 3.1% following the announcement. Further developments continued to impact investor sentiment, culminating in a major stock decline of over 24% following the December 2025 announcement that the FDA had accepted the BLA on a standard review basis rather than an accelerated one.

Looking Ahead

As the Pomerantz Law Firm proceeds with this class action lawsuit, it underscores the importance of corporate accountability and investor rights in the biotechnology sector. Their history of fighting for the victims of securities fraud positions them as a key player in this legal battle, representing those affected by Inovio’s alleged misleading practices.

The outcome of this lawsuit could have implications extending beyond immediate investor compensation, as it highlights broader concerns about transparency and accountability in biotech operations. Investors are encouraged to stay informed and consider their options in relation to their holdings in Inovio Pharmaceuticals. The Pomerantz Law Firm remains committed to representing the interests of shareholders and will continue to provide updates as the case progresses.